Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roya Zoraghi

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2002
The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma bruceiRoya Zoraghi, Thomas Seebeck
Current Opinion in Microbiology|August 14, 2013
Protein interaction networks as starting points to identify novel antimicrobial drug targetsRoya Zoraghi, Neil E Reiner
Cellular Signalling|August 12, 2009
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzymeJackie D Corbin, Roya Zoraghi, Sharron H Francis
Molecular Pharmacology|January 27, 2004
Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteinsRoya Zoraghi, Jackie D Corbin, Sharron H Francis
Biochemistry|November 6, 2007
Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitorsRoya Zoraghi, Sharron H Francis, Jackie D Corbin
The Journal of Biological Chemistry|January 13, 2006
Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinityRoya Zoraghi, Jackie D Corbin, Sharron H Francis
Biochemistry|August 19, 2007
N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerizationJames L Weeks, Roya Zoraghi, Sharron H Francis, et al.
The Journal of Biological Chemistry|January 29, 2005
Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulationRoya Zoraghi, Emmanuel P Bessay, Jackie D Corbin, et al.
Frontiers in Bioscience : a Journal and Virtual Library|June 23, 2005
Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transportersSharron H Francis, Mitsi A Blount, Roya Zoraghi, et al.
Molecular Pharmacology|August 24, 2006
A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerizationMitsi A Blount, Roya Zoraghi, Hengming Ke, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2002
The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma bruceiRoya Zoraghi, Thomas Seebeck
Current Opinion in Microbiology|August 14, 2013
Protein interaction networks as starting points to identify novel antimicrobial drug targetsRoya Zoraghi, Neil E Reiner
Cellular Signalling|August 12, 2009
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzymeJackie D Corbin, Roya Zoraghi, Sharron H Francis
Molecular Pharmacology|January 27, 2004
Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteinsRoya Zoraghi, Jackie D Corbin, Sharron H Francis
Biochemistry|November 6, 2007
Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitorsRoya Zoraghi, Sharron H Francis, Jackie D Corbin
The Journal of Biological Chemistry|January 13, 2006
Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinityRoya Zoraghi, Jackie D Corbin, Sharron H Francis
Biochemistry|August 19, 2007
N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerizationJames L Weeks, Roya Zoraghi, Sharron H Francis, et al.
The Journal of Biological Chemistry|January 29, 2005
Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulationRoya Zoraghi, Emmanuel P Bessay, Jackie D Corbin, et al.
Frontiers in Bioscience : a Journal and Virtual Library|June 23, 2005
Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transportersSharron H Francis, Mitsi A Blount, Roya Zoraghi, et al.
Molecular Pharmacology|August 24, 2006
A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerizationMitsi A Blount, Roya Zoraghi, Hengming Ke, et al.
Pageof 3